Open AccessPlasma neurofilament light chain predicts progression in progressive supranuclear palsy
Author(s) -
Rojas Julio C.,
Karydas Anna,
Bang Jee,
Tsai Richard M.,
Blennow Kaj,
Liman Victor,
Kramer Joel H.,
Rosen Howard,
Miller Bruce L.,
Zetterberg Henrik,
Boxer Adam L.
Publication year - 2016
Publication title -
annals of clinical and translational neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.824
H-Index - 42
ISSN - 2328-9503
DOI - 10.1002/acn3.290
Subject(s) - progressive supranuclear palsy , medicine , cohort , cerebrospinal fluid , gastroenterology , atrophy , pathology
Objective Blood‐based biomarkers for neurodegenerative conditions could improve diagnosis and treatment development. Neurofilament light chain (NfL), a marker of axonal injury, is elevated in cerebrospinal fluid ( CSF ) of patients with progressive supranuclear palsy ( PSP ). The goal of this study was to determine the diagnostic and prognostic value of plasma NfL in patients with PSP . Methods Plasma NfL was measured with ultrasensitive digital immunoassay‐based technology at baseline and 1‐year follow‐up in a pilot cohort of 15 PSP patients and 12 healthy controls, and a validation cohort of 147 PSP patients. Mixed linear models tested the ability of plasma NfL to predict neurological, cognitive and functional decline, and brain atrophy. Results Baseline mean plasma NfL levels were elevated in PSP patients (31 ± 4 pg/mL, vs. control, 17.5 ± 1 pg/mL, P < 0.05) and this difference persisted at follow‐up. A cutoff value of 20 pg/mL related to the diagnosis of PSP with a sensitivity of 0.80 and specificity of 0.83 (positive likelihood ratio = 4.7 and a negative likelihood radio of 0.24). Patients with higher NfL levels had more severe neurological ( PSPRS , −36.9% vs. −28.9%, P = 0.04), functional ( SEADL , −38.2% vs. −20%, P = 0.03), and neuropsychological ( RBANS , −23.9% vs. −12.3%, P = 001) deterioration over 1 year. Higher baseline NfL predicted greater whole‐brain and superior cerebellar peduncle volume loss. Plasma and CSF NfL were significantly correlated ( r = 0.74, P = 0.002). Interpretation Plasma NfL is elevated in PSP and could be of value as a biomarker both to assist clinical diagnosis and to monitor pharmacodynamic effects on the neurodegenerative process in clinical trials.